top of page
Copy of MedMira receives Health Canada approval for its Reveal® G4 Rapid HIV-1/2 Test for Point-of-Care use
Halifax, Nova Scotia – January 14, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today the approval from...
MedMira
14. Jan. 20253 Min. Lesezeit
Copy of MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Halifax, Nova Scotia, 9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing...
MedMira
9. Jan. 20254 Min. Lesezeit
MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV
Halifax, Nova Scotia - December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24,...
MedMira
24. Dez. 20245 Min. Lesezeit
MedMira Announces the appointment of Vice President of Commercial Operations
Halifax, Nova Scotia, October 3, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) today announced the appointment of Nicole Crenshaw as...
MedMira
3. Okt. 20243 Min. Lesezeit
Kopie der klinischen Studien mit dem Multiplo® Complete Syphilis (TP/nTP)-Antikörpertest beginnen - ein potenzieller Wendepunkt zur Bewältigung der Syphilis-Gesundheitskrise in Kanada
Halifax, Nova Scotia, 13. August 2024 – Heute gibt MedMira Inc. (MedMira) (TSXV: MIR) bekannt, dass es umfassende klinische Studien für...
MedMira
13. Aug. 20245 Min. Lesezeit
MedMira Announces the Hire of Vice President of Business Development
Halifax, Nova Scotia, 30 April, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to announce the expansion of their...
MedMira
30. Apr. 20242 Min. Lesezeit
bottom of page